Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
PolyPeptide Group AGJohnson & Johnson
Last price
CHF 42.05$273.20
Currency
CHF
USD
CHF 1.4B$658B
103.1241.49
CHF 0.41$6.58
1.000.21
0$5.28
01.96%
Sector
HealthHealth
Employees
1,460138,200
Ticker
Fr. PPGN$JNJ
Primary listing
XSWXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in Fr.PPGN or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.